Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

2 articles

Newest first

Protocol 2019CC BY-NCFree full text · non-commercial reuse

Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.

Berzenn Urbi, Simon Broadley, Richard Bedlack, Ethan Russo, Arman Sabet

Introduction Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3-5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy of cannabinoids in extending the survival and slowing of disease progression i…

BMJ Open PubMed Central Open Access

Open article record in new tab ↗

Research Article 2018CC BYFree full text

Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset.

Chunrong Tao, Steve Simpson Jr., Bruce V. Taylor, Leigh Blizzard, Robyn M. Lucas, Anne-Louise Ponsonby +3 more

Background: Age at symptom onset (ASO) is a prognostic factor that could affect the accrual of disability in multiple sclerosis (MS) patients. Some factors are known to influence the risk of multiple sclerosis (MS), but their influence on the ASO is less well-investigated. Objective: Examine the associations between known or emerging MS risk factors and ASO. Methods: This was a multicenter study, incident cases (n…

Frontiers in Neurology PubMed Central Open Access